Great advances in knowledge of neuroendocrine lung tumours have resulted in the past 20 years from the application of new techniques, including electron microscopy, cell culture, immunocytochemistry, radioimmunoassay, and more recently molecular biology. These techniques have added greatly to our understanding of these complicated and often fatal tumours but they also raise many further questions, to which we do not yet have answers. For pathologists this is reflected in the multiple and at times complicated classifications applied to these tumours, depending on the techniques used and the tissues studied. For clinicians this explosion in knowledge has provided many new avenues for investigation and the possibility of developing new therapeutic tools. The subject of neuroendocrine differentiation in lung tumours is only now being unravelled. These new findings may soon help to unlock some of the secrets of lung carcinogenesis and help patients by providing diagnostic, prognostic, and possibly therapeutic information.
Neuroendocrine cells in the lung It was Feyrter' in 1938 who first described clear cells in the respiratory epithelium of the human airway and included them in a "diffuse endocrine system" with other clear cells in the gastrointestinal tract and pancreas. Frohlich2 found that these cells were argyrophilic (taking up silver salts) and with foresight (but no evidence) he considered them to be chemoreceptors capable of monitoring gas This widespread collection of peptide containing cells and nerves is known as the diffuse neuroendocrine system.67 All these peptides have potent actions on airway smooth muscle, vasomotor tone, and airway secretion and have been proposed as important modulators of physiological changes in the lung.8 The peptides may carry out their effects in a classical endocrine manner via the bloodstream, via nerve transmission (neuroendocrine), or in a local ("paracrine") fashion. Not surprisingly, given the extensive nature of this peptide containing system in the human respiratory tract, lung tumours can produce many of these neuroendocrine features.
Neuroendocrine lung tumour classification
The secretion of what were originally considered to be "ectopic" hormones by lung tumours has been known for some time.9 Adrenocortical overactivity leading to Cushing's syndrome was described in a patient with lung carcinoma in 1928. Sensitive assay and cell culture techniques have permitted the detection of peptide hormone secretion by tumours, particularly lung tumours,'°0 1 in the absence of clinically overt syndromes. Overt endocrinological disturbance and biologically active peptide hormone production is common in small cell carcinomas and carcinoid tumours; but almost all lung cancers, irrespective of histological type, are capable of producing small amounts of peptide.'2 Both carcinoid tumours and small cell carcinomas can be recognised by light microscopy. Dense core neurosecretory granules in small cell carcinomas and carcinoid tumours added an ultrastructural feature to establish neuroendocrine differentiation4 13 and showed the close association between these tumours and normal pulmonary endocrine cells, which also contain dense core granules. Thus both carcinoid tumours and small cell carcinomas are considered neuroendocrine tumours of the lung and included in the World Health Organisation histological classification of lung tumours.'4 Carcinoid tumours are considered to form the benign end of the spectrum and small cell carcinomas the highly malignant end. A distinct subgroup of carcinoid tumours, labelled atypical carcinoids, with histological and clinical evidence of malignancy and with a high rate of metastases,'5 were described in 1972. These lung neuroendocrine tumours form a link between carcinoid tumours and small cell carcinomas. To reflect the overlap between these tumours it was suggested that 27 He considers that neuroendocrine differentiation in non-small cell carcinomas indicates aggressive behaviour and suggests that chemotherapy should be assessed for such tumours.
This classification is useful in delineating a spectrum of endocrine lung tumours with predictable behaviour but falls short on several points. Firstly, the description of the neuroendocrine carcinoma of intermediate cell type is too vague and non-specific to allow this to be separated from other undifferentiated tumours by light microscopy in my experience. Secondly, it is unfortunate that this category was named intermediate cell type as it is often confused with the "intermediate" small cell carcinoma subgroup of the WHO classification. 4 Thirdly, the classification presupposes a histogenetic relationship that has not yet been established. There is now sufficient evidence to regard carcinoid tumours as separate from small cell carcinomas and other lung tumours. Carcinoid tumours occur in a younger population and are not related to smoking habits or other risk factors for the more common forms of lung cancer. Furthermore, small cell carcinomas are rarely seen in association with carcinoid tumours. The initial response of a small cell carcinoma to combination chemotherapy and the poor long term prognosis contrast with the chemoresistance and good prognosis of most carcinoid tumours. These observations call into question the value of attempts to devise a terminology for a spectrum of neuroendocrine tumours and the classification of these tumours remains in a state of flux.
Difficulties in the diagnosis of neuroendocrine lung tumours The more recent classifications of neuroendocrine lung tumours are difficult for pathologists to apply, particularly for the non-small cell types. Classification requires basic light microscopy plus electron microscopy and the use of immunocytochemical markers, which are expensive and time consuming. A patient with an unusual lung tumour suspected of being a neuroendocrine tumour should probably be referred to a specialist centre for appropriate investigations; formal follow up is essential to establish their behaviour and prognosis.
A second problem is that lung tumours show heterogeneity with both light microscopy and electron microscopy, which can lead to problems in interpreting neuroendocrine features. Up to 7% of lung tumours have a mixed morphology according to light microscopic appearances. Multiple sampling of a tumour by electron microscopy may reveal glandular, squamous, and neuroendocrine At electron microscopy the definition of a dense core neurosecretory granule, the hallmark of neuroendocrine differentiation, is not clear and several studies show a wide divergence in the size, shape, and distribution of these granules. Differentiating them from small lysosomes may be difficult.
Finally, the specificity of the general neuroendocrine markers has been questioned as these markers have been found in non-neuroendocrine tumours, such as breast or We found that, although neurone specific enolase and PGP9.5 are positive in most neuroendocrine tumours,34 they are also present in 10-60% of non-neuroendocrine lung tumours and are not now considered as reliable markers of neuroendocrine differention. Chromogranin, Leu-7, and synaptophysin appear to be more useful markers but they stain fewer neuroendocrine tumours than neurone specific enolase and PGP9.5.46' Use of a panel of markers rather than a single marker is advised, with a combination of neurone specific enolase, PGP9.5, chromogranin, and synapto-physin. A positive result with two of the four markers is recommended before a tumour can be labelled as neuroendocrine.
Conclusion
Neuroendocrine lung tumours are proving a fruitful area of research for understanding the basic mechanisms of carcinogenesis. Rapid advances in the molecular and cell biology of these tumours should help to determine their spectrum of behaviour. New studies are essential, using light microscopy, electron microscopy, immunocytochemistry, and molecular biology techniques, for clarifying different subtypes and designing future treatments, particularly now that many growth factors are known to be produced by these tumours. A classification based on morphological and functional criteria may prove to be of therapeutic importance in the future. 
